Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
Baxter
Mallinckrodt
Express Scripts
Harvard Business School

Last Updated: January 26, 2022

DrugPatentWatch Database Preview

Claims for Patent: 9,101,647

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 9,101,647
Title:Composition and method for inner ear sensory hair cell regeneration and replacement
Abstract: A composition and method for replacement and regeneration of hair cells of the inner ear is provided. The composition comprises an active agent in an amount effective to decrease Hes1 gene expression in a tissue of the inner ear. The active agent can be short interfering RNA (siRNA) molecules encapsulated in a biodegradable nanoparticle. The method involves administering a solution to the inner ear where the solution contains an active agent in an amount effective to decrease Hes1 gene expression.
Inventor(s): Kopke; Richard D. (Oklahoma City, OK)
Assignee: HOUGH EAR INSTITUTE (Oklahoma City, OK)
Application Number:13/701,550
Patent Claims:1. A composition for regenerating hair cells of the inner ear comprising: (a) magnetically responsive nanoparticles comprising poly(lactic-co-glycolic acid) and an siRNA molecule that decreases expression of a Hes1 gene in a tissue of the inner ear and (b) a pharmaceutically acceptable carrier.

2. The composition of claim 1, wherein the composition comprises one or more of: (i) an siRNA molecule comprising SEQ ID NO. 3 and a complementary sequence thereof; (ii) an siRNA molecule comprising SEQ ID NO. 4 and a complementary sequence thereof; (iii) an siRNA molecule comprising SEQ ID NO. 5 and a complementary sequence thereof; (iv) an siRNA molecule comprising SEQ ID NO. 6 and a complementary sequence thereof; (v) an siRNA molecule comprising SEQ ID NO. 7 and a complementary sequence thereof; and (vi) an siRNA molecule comprising SEQ ID NO. 8 and a complementary sequence thereof.

3. The composition of claim 1, wherein the composition comprises one or more of (i) an siRNA molecule comprising SEQ ID NO. 3 and SEQ ID NO. 4, (ii) an siRNA molecule comprising SEQ ID NO. 5 and SEQ ID NO. 6, and (iii) an siRNA molecule comprising SEQ ID NO. 7 and SEQ ID NO. 8.

4. The composition of claim 1, wherein the siRNA molecule comprises SEQ ID NO. 7 and SEQ ID NO. 8.

5. The composition of claim 1, wherein the nanoparticles comprise superparamagnetic iron oxide.

6. The composition of claim 1, wherein the nanoparticles comprise from about 500 to about 1000 siRNA molecules per nanoparticle.

7. The composition of claim 1, wherein the nanoparticles are dispersed in the pharmaceutically acceptable carrier.

8. The composition of claim 7 in which a concentration of the siRNA molecules per milliliter of dispersion ranges from about 50 .mu.g/mL to about 100 .mu.g/mL.

9. The composition of claim 1, wherein the pharmaceutically acceptable carrier is selected from a group consisting of artificial perilymph, 5% dextrose in sterile water, sterile physiologic saline, and phosphate-buffered physiologic saline.

10. The composition of claim 1, where the composition comprises nanoparticles comprising a biodegradable polymer and one or both of (i) an siRNA molecule that decreases expression of a Hes5 gene in a tissue of the inner ear and (ii) an siRNA molecule that decreases expression of a MAPK1 gene in a tissue of the inner ear.

11. The composition of claim 10, wherein the siRNA molecule that decreases expression of the Hes5 gene comprises (i) SEQ ID NO. 9 and a complementary sequence thereof, (ii) SEQ ID NO. 10 and a complementary sequence thereof, (iii) SEQ ID NO. 11 and a complementary sequence thereof, (iv) SEQ ID NO. 12 and a complementary sequence thereof, (v) SEQ ID NO. 13 and a complementary sequence thereof, (vi) SEQ ID NO. 14 and a complementary sequence thereof, or (vii) combinations of any of these.

12. The composition of claim 10, wherein the siRNA molecule that decreases expression of the MAPK1 gene comprises (i) SEQ ID NO. 15 and a complementary sequence thereof, (ii) SEQ ID NO. 16 and a complementary sequence thereof, or (iii) a combination of these.

13. A method of regenerating hair cells of an inner ear of a mammal comprising: applying to the inner ear of a mammal in need thereof an amount of biodegradable nanoparticles comprising an siRNA molecule that decreases expression of a Hes 1 gene in a tissue of the inner ear effective to regenerate hair cells in an inner ear of said mammal.

14. The method of claim 13, wherein the applying comprises transtympanic administration.

15. The method of claim 13, wherein the applying comprises a direct injection through the round window membrane.

16. The method of claim 13, wherein the nanoparticles further comprise superparamagnetic iron oxide.

17. The method of claim 16, wherein the applying comprises using magnetic force to transport the nanoparticles across the round window membrane.

18. The method of claim 13, wherein the nanoparticles comprise one or more of: (i) an siRNA molecule comprising SEQ ID NO. 3 and a complementary sequence thereof; (ii) an siRNA molecule comprising SEQ ID NO. 4 and a complementary sequence thereof; (iii) an siRNA molecule comprising SEQ ID NO. 5 and a complementary sequence thereof; (iv) an siRNA molecule comprising SEQ ID NO. 6 and a complementary sequence thereof; (v) an siRNA molecule comprising SEQ ID NO. 7 and a complementary sequence thereof; and (vi) an siRNA molecule comprising SEQ ID NO. 8 and a complementary sequence thereof.

19. The method of claim 13, wherein the nanoparticles comprise one or more of (i) an siRNA molecule comprising SEQ ID NO. 3 and SEQ ID NO. 4, (ii) an siRNA molecule comprising SEQ ID NO. 5 and SEQ ID NO. 6, and (iii) an siRNA molecule comprising SEQ ID NO. 7 and SEQ ID NO. 8.

20. The method of claim 13, wherein the siRNA molecule comprises SEQ ID NO. 7 and SEQ ID NO. 8.

21. A magnetically responsive nanoparticle for regenerating hair cells of the inner ear, comprising a poly(lactic-co-glycolic acid) and an siRNA molecule that decreases expression of a Hes1 gene in a tissue of the inner ear.

22. The nanoparticle of claim 21, wherein the nanoparticle comprises one or more of: (i) an siRNA molecule comprising SEQ ID NO. 3 and a complementary sequence thereof; (ii) an siRNA molecule comprising SEQ ID NO. 4 and a complementary sequence thereof; (iii) an siRNA molecule comprising SEQ ID NO. 5 and a complementary sequence thereof; (iv) an siRNA molecule comprising SEQ ID NO. 6 and a complementary sequence thereof; (v) an siRNA molecule comprising SEQ ID NO. 7 and a complementary sequence thereof; and (vi) an siRNA molecule comprising SEQ ID NO. 8 and a complementary sequence thereof.

23. The nanoparticle of claim 21, wherein the nanoparticle comprises one or more of (i) an siRNA molecule comprising SEQ ID NO. 3 and SEQ ID NO. 4, (ii) an siRNA molecule comprising SEQ ID NO. 5 and SEQ ID NO. 6, and (iii) an siRNA molecule comprising SEQ ID NO. 7 and SEQ ID NO. 8.

24. The nanoparticle of claim 21, wherein the siRNA molecule comprises SEQ ID NO. 7 and SEQ ID NO. 8.

25. The nanoparticle of claim 21, wherein the nanoparticle comprises superparamagnetic iron oxide.

26. The nanoparticle of claim 21, wherein nanoparticle comprises from about 500 to about 1000 siRNA molecules.

27. The nanoparticle of claim 21, where the nanoparticle further comprises one or both of (i) an siRNA molecule that decreases expression of a Hes5 gene in a tissue of the inner ear and (ii) an siRNA molecule that decreases expression of a MAPK1 gene in a tissue of the inner ear.

28. The nanoparticle of claim 27, wherein the siRNA molecule that decreases expression of the Hes5 gene comprises (i) SEQ ID NO. 9 and a complementary sequence thereof, (ii) SEQ ID NO. 10 and a complementary sequence thereof, (iii) SEQ ID NO. 11 and a complementary sequence thereof, (iv) SEQ ID NO. 12 and a complementary sequence thereof, (v) SEQ ID NO. 13 and a complementary sequence thereof, (vi) SEQ ID NO. 14 and a complementary sequence thereof, or (vii) combinations of any of these.

29. The nanoparticle of claim 27, wherein the siRNA molecule that decreases expression of the MAPK1 gene comprises (i) SEQ ID NO. 15 and a complementary sequence thereof, (ii) SEQ ID NO. 16 and a complementary sequence thereof, or (iii) a combination of these.

30. The composition of claim 1, where the nanoparticles further comprise one or both of (i) an siRNA molecule that decreases expression of a Hes5 gene in a tissue of the inner ear and (ii) an siRNA molecule that decreases expression of a MAPK1 gene in a tissue of the inner ear.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
Express Scripts
AstraZeneca
Medtronic
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.